Non-phospho-YAP1-S127 Rabbit pAb for WB, IHC-P, ELISA - P46937

Core Product Specifications and Parameters

Biological Background: YAP1 Function and Localization

• Transcriptional coactivator YAP1 (Yes-associated protein, YAP65) is the core downstream effector of the Hippo kinase cascade (STK3/4–LATS1/2) that restricts proliferation and promotes apoptosis, thereby controlling organ size and suppressing tumors. (PubMed:17974916, PubMed:18280240, PubMed:18579750) Related references: PMID:17974916 PMID:18280240 PMID:18579750
• LATS1/2-mediated phosphorylation at Ser127 results in cytoplasmic retention and inactivation; the non-phosphorylated form translocates to the nucleus and, in complex with TEAD transcription factors, drives expression of genes supporting cell growth, anchorage-independent survival, and epithelial-mesenchymal transition (EMT). (PubMed:18158288, PubMed:26598551, PubMed:34404733) Related references: PMID:18158288 PMID:26598551 PMID:34404733
• Beyond Hippo, YAP1 controls cortical actomyosin and 3D tissue architecture by inducing ARHGAP18 to suppress F-actin polymerization. (PubMed:25778702) Related references: PMID:25778702
• YAP1 acts as a transcriptional corepressor for TEAD4 at the AURKA and PLK1 promoters, thereby inhibiting ciliogenesis. (PubMed:25849865) Related references: PMID:25849865
• In steroid receptor signaling, YAP1 synergizes with WBP2 to enhance progesterone receptor (PGR) activity and can transactivate the ERBB4 cytoplasmic fragment (isoform 3 CTF). (PubMed:16772533) Related references: PMID:16772533
• YAP1 shuttles between the cytoplasm, nucleus, tight junctions, and plasma membrane; its subcellular localization dictates its oncogenic or tumor-suppressive functions.
• Clinically, YAP1 expression is elevated in subsets of liver and prostate cancers; in Huntington disease, an isoform lacking the transactivation domain accumulates in striatal neurons (at protein level).
• Post‑translational modifications include phosphorylation (multiple residues), ubiquitination, and potentially acetylation; it is classified as a proto‑oncogene and reference proteome member.

Experimental Guidance and Technical Tips

• The immunogen (residues 50–150) spans the LATS1/2 phosphorylation site (Ser127); thus, the antibody specifically recognizes the non‑phosphorylated, active form. Inclusion of phosphatase inhibitors during lysis is recommended to preserve the signal.
• For western blot, expect a primary band at ~54 kDa. Additional bands may appear from alternative splicing or post‑translational modifications; validate using siRNA knockdown or peptide blocking.
• In immunohistochemistry (IHC‑P), nuclear staining indicates active YAP1; cytoplasmic/membrane staining should be interpreted cautiously. Consider antigen retrieval conditions and include a non‑phospho‑blocking peptide control.
• For ELISA, use the immunizing peptide to confirm specificity; cross‑reactivity with mouse and rat allows comparative studies across species.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio supports diagnostic and research organizations by offering integrated access to IVD raw materials, including validated antibody pairs and bulk ancillary reagents. This Non-phospho-YAP1-S127 Rabbit pAb is tailored for Hippo pathway and cancer biomarker studies, with complementary reagents available for assay development. Our sourcing network enables procurement of rare‑target antibodies and custom production to bridge the gap from concept to clinical application.